Watson’s Transformative Deal-Making
A steady stream of M&A and licensing activity, starting with the buyout of Andrx in 2006, spurred Watson’s transformation into a global specialty pharma. This led the way to the 2012 merger with Actavis and now the proposed buyout of Forest, creating a new, global specialty and generics player.
You may also be interested in...
The US agency’s 2021 device funding request for $21m above its 2020 budget will be frozen under a continuing resolution, making planning difficult.
Bakul Patel, director of the US agency’s new Digital Health Center of Excellence, tells Medtech Insight he’s looking to hire staff that want to shape the digital health regulatory landscape.
No device-related warning letters were released by the US FDA the week of 29 September.